G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
It plans to deliver over 300 million doses to the Indian government
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
This product will be manufactured at Lupin's Goa facility in India
The Home Healthcare market is expected to be US $ 14.2 by 2025
Subscribe To Our Newsletter & Stay Updated
